EHA Scientific Working Groups
Scientific Working Groups (SWGs) seek to create and/or support scientific networks that could serve under the umbrella of EHA. They promote high-quality science within the hematology community. The SWGs are open to anyone with a professional interest in the particular area of the SWG. EHA currently supports 19 SWGs.
Click Titles below to expand.
Acute Myeloid Leukemiaclick to expand
Goal: The group constitutes a platform for translational research and provides a forum to bridge gaps between basic scientists and clinicians treating patients with Acute Myeloid Leukemia (AML). The implications of high throughput sequencing technologies and minimal residual disease assessment to clinical trial design are high priorities.
Chair: Gert Ossenkoppele
Aging and Hematologyclick to expand
Goal: Screening tools for fitness, survival, toxicity and dependence as well as research in immunosenescence are the main objectives of the group. In general the group would like to work on a registry of ongoing trials in older patients with malignant hemopathies.
Chair: D Bron
Bleeding and Thrombosisclick to expand
Goal: The group wishes to develop a task force to identify the causes of thrombosis and bleeding in onco-hematological patients. In the future the SWG would like to establish a network for collaborative clinical studies on thrombotic markers to predict thrombosis in cancer patients.
Chair: Anna Falanga
Chronic Myeloid Leukemia click to expand
Goal: The SWG aims to bring to the attention of the EHA Congress audience, biological data relating to Chronic Myeloid Leukemia (CML) that has not been a focus of attention in any other part of the EHA meeting. In general, clinical data tends to be very well covered by the SWG.
Chair: R Hehlmann
European MCL Networkclick to expand
Goal: The group focuses on the evaluation of promising new treatment options in Mantle Cell Lymphoma (MCL), in order to improve the clinical course of this aggressive lymphoma in prospective, randomized studies. The European MCL Network is therefore an important and attractive organization for the development and implementation of early (phase I/II) clinical trials on MCL.
Chair: M Dreyling
ESLHO-EuroMRD and ESLHO-EuroFlowclick to expand
Goal: The objectives of the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO) are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies in addition to quality control and education of laboratory diagnostics focused on lymphoid malignancies.
Chair: J van Dongen
European Research Initiative on CLL click to expand
Goal: The group is devoted to improving the outcomes of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. As part of the European LeukemiaNet and ERIC, the group has the following objectives: research in all aspects of CLL and related disorders, exchange and dissemination of knowledge and information in CLL and related disorders, education and instruction in CLL and related disorders.
Chair: Paolo Ghia
European Working Group for Adult ALL click to expand
Goal: The EWALL Group is a cooperation of Study Groups for Adult Acute Lymphoblastic Leukemia (ALL) and includes the national trials for adult ALL in Europe. Its major purpose is collaboration in clinical trials, diagnostics, translational research, retrospective analysis and patient information.
Chair: N Gökbuget
European Working Group for Philadelphia-negative Myeloproliferative Neoplasmsclick to expand
Goal: The SWG aims to spread the excellence through educational sessions, focus on young investigators, promote research in MPNs and facilitate academic collaboration.
Chair: JJ Kiladjian
Immune therapies for hematologic disorders click to expand
Goal: The group would like to cooperate on studies and contribute to scientific exchange at the EHA meetings as well as provide input for the EHA Learning Center. One of the aims is also to interact with disease focused SWGs.
Chair: H Einsele
European Working Group for Stem Cellsclick to expand
Goal: The goal is to bring together researchers, biologists and clinicians dealing with hematopoietic malignancies to share the recent advances in the new field of malignant and non-malignant stem cells.
Chair: D Bonnet
Granulocyte and Constitutional Marrow Failure Disorderclick to expand
Goal: The SWG’s mission is to improve and voice knowledge on granulocytes/monocytes and related disorders, which then facilitates the exchange of scientific and clinical information and experience in the framework of coordinated actions. Attention is focused on junior clinicians and researchers through educational activities.
Chair: C Dufour
Leukemia diagnosis: morphology and flow cytometryclick to expand
Goal: The SWG on ‘Leukemia diagnosis: morphology and flow cytometry’ has the same aims as the European LeukemiaNet WP10 on diagnosis, namely to promote consensus recommendations on the diagnosis of leukemia. The group is also interested in minimal residual disease and works together with the group devoted to myelodysplasia.
Chair: MC Béné
Lymphomaclick to expand
Goal: The SWG Lymphoma aims to result in an organization that initiates early phase I/II (investigator-initiated) studies across lymphoma subtypes using targeted treatments based on deregulation of signaling and survival pathways. The group would like to form a platform for innovative diagnostic techniques in the field of lymphoma and create a clinical trials network for early clinical trials across lymphoma subtypes. The SWG Lymphoma will collaborate closely with the European MCL Network, with ERIC and with the SWG MM.
Chair: MJ Kersten
Mesenchymal stromal cellsclick to expand
Goal: The SWG would like to discuss progress in the field of mesenchymal stromal cell biology and treatment as well as develop common protocols for expansion of MSCs. Furthermore the group aims to develop new clinical studies using stromal cells for immunemodulation and to organize scientific meetings to discuss progress in the field.
Chair: W Fibbe
Multiple myeloma click to expand
Goal: The SWG on Multiple myeloma supports a range of clinical trials and biological research, which are presented at several international meetings and disseminated through international journals. The group closely collaborates with the European Myeloma Network (EMN) and the patient organizations Myeloma Euronet and the European Myeloma Platform.
Chair: P Sonneveld
Myelodysplastic syndromesclick to expand
Goal: In cooperation with the ad hoc work package of ELN the purpose of the group is to stimulate cooperation in EU on clinical trials and biological studies in MDS.
Chair: U Platzbecker
Precision Medicineclick to expand
Goal: The group constitutes a platform for genomic profiling in clinical practice and provides a forum to promote a classification of hematologic malignancies on the basis of genetics. Furthermore the activities and high priority of this SWG are the need for publically available centralized databases for genomic research and clinical decision-making as well as precision treatment and clinical trials.
Chair: Mario Cazzola
Red cell and iron click to expand
Goal: To highlight areas of research and scientific breakthroughs, in red blood haematology and iron, which have not been focussed on in any other part of the EHA meeting. Topics are selected after consultation with members of the group and any others with a special interest in red blood cell haematology.
Chair: A Iolascon
Thrombocytopenias and platelet function disorders click to expand
Goal: The mission of the EHA Scientific Working Group on Thrombocytopenia (SWGT) includes the intention to incentivize the collaboration among scientists involved in research on platelet disorders and to promote educational opportunities for young specialists and trainees. This working party collaborates closely to improve the diagnosis, pathogenesis and treatment of patients with ITP. The group is working on terms and definitions in addition to bleeding score assessment.
Chair: C Balduini
Quality of life and symptoms click to expand
Goal: The priorities of this group are the dissemination of knowledge among physicians and researchers with a view to maintaining high common standards in the field of quality of life research, development of both practical and clinical research recommendations on quality of life and symptom assessment in hemato-oncology.
Chair: E Oliva